about
Targeted therapy for advanced renal cell carcinomaCell signaling by receptor tyrosine kinasesAxitinib for the management of metastatic renal cell carcinomaSpotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectivesMolecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?Combination therapy for renal cell cancer: what are possible options?Discovery of Diverse Small-Molecule Inhibitors of Mammalian Sterile20-like Kinase 3 (MST3)Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell CarcinomaSunitinib in the treatment of metastatic renal cell carcinomaAdaptation to antiangiogenic therapy in neurological tumorsSunitinib in solid tumorsOverall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomaA phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma(3)D [corrected] quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapiesAssociation Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug ReactionA meta-analysis of threats to valid clinical inference in preclinical research of sunitinibPhase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastasesRenal cell cancer: overview of the current therapeutic landscape.Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Characterization of a novel angiogenic model based on stable, fluorescently labelled endothelial cell lines amenable to scale-up for high content screening.Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown primary).Drug-induced immune thrombocytopenic purpura secondary to sunitinib.Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinomaPhase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma.Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in KoreaSunitinib in metastatic renal cell carcinoma patients with brain metastases.Phase II study of sunitinib malate in patients with recurrent high-grade glioma.Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group.A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancerSunitinib-associated pseudothrombocytopenia induced by IgM antibody.Continuous daily sunitinib for recurrent glioblastoma.Drug-induced immune-mediated thrombocytopenia secondary to sunitinib in a patient with metastatic renal cell carcinoma: a case report.Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapyPhase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumorSunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience.Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma.
P2860
Q24242946-CE21A34C-54FF-4E21-8CD9-C5D502B3BF40Q24598357-7E60DA74-225B-46DB-B3FF-57ADB17F218DQ24613720-99E453BA-B4E0-4526-9BA8-12983D928827Q26751274-95EE5F2D-1C23-4AD9-B9D4-BB04499F7CD7Q26825512-F53D777C-3F15-4962-9A10-7E3930FB03FEQ27011663-00CF88F1-131C-4E6D-BCE6-EC5C013E08C5Q27704783-8D68ACF3-F1BB-40CE-BBD6-6F4C44AB4673Q28066747-639298EB-6614-4E36-B24D-5BE3D7220183Q28072057-B16A3C47-3A58-47AA-9982-1587561077C6Q28082908-F2C05984-633D-4A13-9754-8EC7AB2237B9Q28245467-61AFE885-4984-487E-8539-87A48EAB8FB3Q28247085-957928D6-F65C-4E50-A94F-75578ED8F37AQ28304566-D5E4AD2E-5A80-46E3-AF99-F87750030ADAQ28488869-C1E1E24E-3C53-4617-9770-1685BEB68BC7Q28550377-3492F8A4-F1D9-41B5-BDF2-E6F6595AFAD2Q28606538-89C8D186-3035-460A-B3B3-81D9C3C93771Q28727917-73550AB8-4083-4A5E-9193-2BEBD6FF3273Q30248354-22035DA1-5167-4362-9348-5E9E62C43442Q30313895-4CA42016-E1BF-4D20-9A55-526AFCE60CA2Q30479629-412D187F-ADA7-4C31-B68A-B2C541265637Q30531493-1BD91642-0DB6-4A8A-9667-6C75C58D4385Q33310987-E6EC3782-0405-4ADA-85F9-3DF98D3868F4Q33380172-19269322-E562-44EC-95DD-28A0C82FF1CEQ33383268-E2C075C2-F32A-48D8-859A-0F9795743D6BQ33383270-1FC22092-195B-4DF4-98F0-93186DA84605Q33384665-7DD89825-CAAF-4BD2-AABE-1C193E5B79F8Q33385981-A520DF27-8AE1-4448-AFC2-25A816BE2D58Q33391978-5BC011D5-B590-4674-8F27-C402708AA2ECQ33392046-72F21E58-CAE8-4C96-B987-DA9DAEDD2579Q33394774-55B47A6E-58B8-47C6-B23D-F7E159CCD228Q33397590-01D3F9CF-730B-42C7-B981-0C5EF855B7C1Q33403806-7B878BFD-DA01-46CA-B50A-33482486F168Q33403947-1C13FAF1-3AC7-4C13-BEB5-F1B77A84DFA0Q33406106-88075E2A-F825-4D1C-BA98-A5934530CCD3Q33409913-AF447F8B-6F71-46C5-A771-8DF84473634FQ33416940-AD6042D0-7C04-4436-B234-A7F56A0CA878Q33419097-2896C395-3B24-4247-B691-BD75B453B5A0Q33425872-5321F56D-E9F1-4D37-A3A3-A5D26AE62CDAQ33434845-662FB5E6-A991-4A76-94BD-8E38485B1640Q33434933-04AAECA6-53F6-4D72-ACBB-71C1AA62C1D8
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Sunitinib: from rational design to clinical efficacy.
@en
type
label
Sunitinib: from rational design to clinical efficacy.
@en
prefLabel
Sunitinib: from rational design to clinical efficacy.
@en
P356
P1476
Sunitinib: from rational design to clinical efficacy.
@en
P2093
Laura Q M Chow
S Gail Eckhardt
P304
P356
10.1200/JCO.2006.06.3602
P407
P577
2007-03-01T00:00:00Z